Autoinflammatory & rare systemic diseases
Predictors of mortality in sarcoidosis: a nationwide cohort study from the SARCOGEAS registry
Authors' conclusion
n this nationwide, multicentre cohort, mortality was 10.29%. Mortality was independently associated with age, male sex, cardiac and pulmonary parenchymal involvement, while extrathoracic lymphadenopathy was linked to lower mortality.
Study context
- Population
- Adults with sarcoidosis (ATS/ERS/WASOG criteria), Spanish SARCOGEAS registry, 36 hospitals61.4% women
- Participants
- 2,187 adults
- Outcome
- All-cause mortality
Methodological detailsmulticentre, nationwide registry (SARCOGEAS), consecutive enrolment, Kaplan-Meier analysis, multivariable Cox regression
- Multicentre
- Nationwide registry (SARCOGEAS)
- Consecutive enrolment
- Kaplan-Meier analysis
- Multivariable Cox regression
Main finding
As reported in the abstract
median follow-up 5.93 years
Deaths
225
10.29%
Survival at 1 year
99.2%
Survival at 10 years
88.3%
Survival at 20 years
73.2%
Observational data: associations, not effects.
Further findings
Independent predictors of mortality (multivariable Cox)
| Estimate | P value | ||
|---|---|---|---|
| Older age | HR 1.11 (95% CI 1.10–1.13) | ||
| Male sex | HR 1.75 (95% CI 1.31–2.35) | P < 0.001 | |
| Scadding stages II-IVHRs across stages | HR 1.42-2.73 | ||
| Cardiac involvement | HR 1.84 (95% CI 1.05–3.21) | P = 0.033 | |
| Extrathoracic lymphadenopathyAssociated with lower risk | HR 0.63 (95% CI 0.43–0.91) | P = 0.016 | |
| 0.20.5125Hazard ratio (log scale) |
Main causes of death
- Pulmonary
- n=92, 40.9%
- Malignancies
- n=47, 20.9%
- Extrapulmonary
- n=39, 17.3%
- Cardiovascular
- n=24, 10.7%
- Other causes
- n=23, 10.2%
Original publication
Predictors of mortality in sarcoidosis: a nationwide cohort study from the SARCOGEAS registry. Clin Exp Rheumatol. Published 25 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →